MDGL - Barron's cites cancer and weight loss plays for biotech M&A
2024-01-09 11:40:35 ET
More on Madrigal, Viking, etc.
- Madrigal Pharmaceuticals: A Deeper Look At A Looming NASH Play
- Viking: Results From 2 Clinical Trials Of Weight Loss Drug Ahead, Other Catalysts On Tap
- Madrigal Pharmaceuticals: Preparing For Resmetirom's Commercialization In 2024
- Viking Therapeutics rises on Roche acquiring peer Carmot
- Pfizer hits new 52-week low after weight loss setback
For further details see:
Barron’s cites cancer and weight loss plays for biotech M&A